TL;DR
- 1.Only tesamorelin has Phase III RCT data with body composition as a primary endpoint. It reduces visceral fat by roughly 15-20% over 26 weeks. Every trial was in HIV-positive patients with lipodystrophy.
- 2.MK-677's two-year human RCT added 1.1 kg of lean mass and raised IGF-1 by 60% for 24 months straight. It did not significantly reduce fat. It also raised fasting glucose and lowered insulin sensitivity.
- 3.CJC-1295 has never completed a body composition RCT. Its credentials are borrowed from tesamorelin and ipamorelin evidence, not earned in its own trials. The GH and IGF-1 data are real. The fat loss claim is an extrapolation.
- 4.MK-677 and CJC-1295 returned to legal compounding in early 2026 after FDA PCAC review. Tesamorelin remains brand-only (Egrifta and the new weekly Egrifta WR, FDA-approved April 2025).
- 5.Your GHR Exon 3 genotype and insulin-risk variants change which compound is the right call for you. The comparison is not the same for every genotype.
CJC-1295 has never completed a randomized controlled trial with body composition as an endpoint. Not once. And yet it is the foundation of more GH optimization protocols than any other compound in this comparison. If you are comparing tesamorelin vs MK-677 for body composition, CJC-1295 belongs in the conversation only once you understand that its fat-loss and muscle-building credentials are borrowed from other compounds, not earned in its own trials.
Mean visceral fat reduction pooled across five tesamorelin Phase III RCTs in the 2026 meta-analysis published in Obesity Research and Clinical Practice. No other GH peptide has completed a comparable trial.
Three compounds dominate the growth hormone peptide for body composition conversation. Tesamorelin and CJC-1295 are both GHRH analogs: they mimic the hypothalamic signal that tells your pituitary to release GH. CJC-1295 extends that signal from roughly 30 minutes to about 8 days per dose by binding albumin via a drug affinity complex. MK-677 uses an entirely different receptor: it mimics ghrelin and activates the GHS-R1a receptor, a separate pathway that also triggers GH release but simultaneously sends a hunger signal that the GHRH analogs do not.
That mechanistic difference is not a footnote. When your goal is visceral fat reduction, a compound that also makes you hungry is working against you on the caloric side of the equation. The net effect of MK-677 on energy balance is almost never discussed in comparison articles, and it matters for the outcome.
In plain English: Tesamorelin and CJC-1295 walk through the front door of the GH axis. They tell your pituitary to release GH the way your hypothalamus normally would. MK-677 enters through a side door: it mimics ghrelin (the hunger hormone) to get GH released, but ghrelin also makes you hungry. Both routes release GH. The side entrance adds an appetite signal the front door does not.
What Tesamorelin Actually Does to Visceral Fat
Tesamorelin selectively reduces visceral fat without touching subcutaneous fat or BMI. That selectivity is mechanistically unusual and the reason it earned FDA approval in 2010 for HIV-associated lipodystrophy under the brand name Egrifta. Five Phase III RCTs, all in HIV-positive patients, showed consistent 15-20% reductions in visceral adipose tissue (VAT) over 26 weeks. A 2026 meta-analysis of those trials in Obesity Research and Clinical Practice pooled the results: mean VAT reduction of 27.71 cm2 (p less than 0.001), trunk fat loss of 1.18 kg, and an improved VAT/SAT ratio across all five studies.
"Tesamorelin significantly reduced visceral adipose tissue and improved the VAT/SAT ratio without a corresponding reduction in subcutaneous fat, supporting a selective effect on central adiposity."
Obesity Research and Clinical Practice, 2026 (pooled analysis of five tesamorelin RCTs)
A 2024 RCT published in Antiviral Research confirmed the effect in a newer treatment cohort on modern integrase-inhibitor therapy, with both visceral and hepatic fat improving at 26 weeks. The mechanism is consistent across patient populations within the HIV context. The catch is that population. Every tesamorelin RCT enrolled patients with iatrogenic lipodystrophy from antiretroviral therapy. Their VAT accumulation pattern is not identical to metabolic visceral fat in healthy adults who eat well and train hard. Extrapolation from one to the other is mechanistically reasonable, but it is still extrapolation. No completed RCT exists in non-HIV populations with body composition as the primary endpoint.
If you want to understand how your genetics change how much IGF-1 tesamorelin will actually generate for you, your GHR Exon 3 deletion status is the single best predictor. D3 carriers see stronger downstream tissue response per GH pulse. Fl/fl carriers may need longer durations to replicate the trial outcomes.
Regulatory note: Egrifta WR, a new weekly formulation of tesamorelin, received FDA approval in April 2025 via supplemental BLA. As an approved biologic, tesamorelin cannot be legally compounded as a copy. It requires a prescription and the on-label HIV lipodystrophy indication in the US.
MK-677 Built Lean Mass for 24 Months. Fat Loss Was Not in the Data.
The benchmark MK-677 human trial is the Nass et al. two-year RCT published in the Annals of Internal Medicine in 2008. Sixty-five healthy older adults (65 and older) randomized to 25 mg MK-677 daily or placebo for 24 months. It remains the longest continuous human secretagogue trial in the published literature.
Lean mass gained in the MK-677 two-year RCT vs -0.5 kg in placebo. Fat mass was not significantly reduced. IGF-1 stayed 60% above baseline for all 24 months.
- Lean mass: +1.1 kg treatment vs -0.5 kg placebo (statistically significant)
- Fat mass: not significantly reduced in the treatment group
- IGF-1: sustained 60% elevation above baseline for the full 24 months
- Grip strength, gait speed, stair-climb time: no significant improvement on any functional test
- Fasting glucose: elevated in the treatment group
- Fasting insulin: elevated (short-term MK-677 pharmacodynamic studies show 15-34% reduction in insulin sensitivity)
The lean mass finding is real and sustained. But it did not translate into any measurable physical performance improvement over two years. Grip strength, walking speed, and stair-climb time were unchanged relative to placebo despite consistent DEXA-confirmed lean mass gains. One honest interpretation: MK-677 raises IGF-1, which promotes sodium and water retention at the renal tubule. That fluid shift reads as lean mass on body composition scans. The true muscle protein accretion is likely smaller than the 1.1 kg headline implies, which is why the functional tests stayed flat.
The appetite signal is the other side of the trade-off. MK-677 mimics ghrelin, and ghrelin drives caloric intake. Multiple participants in the Nass trial reported increased appetite as a side effect. A compound that makes you hungry is not obviously compatible with a visceral fat reduction goal. The net caloric effect of MK-677 on body fat is compound-level vs behavior-level, and most discussions treat them as independent when they are not.
For context on how the GH receptor genetics that govern MK-677's IGF-1 output work across the GH axis, see the IGF-1 receptor genetics guide.
CJC-1295 Has No Body Composition RCT. Not One.
This is what most comparison articles skip. The Ionescu et al. trial in the Journal of Clinical Endocrinology and Metabolism (2006) is the founding human study for CJC-1295. It enrolled 21 healthy adults and showed 2-10x GH elevation and 1.5-3x IGF-1 elevation lasting 9-11 days after a single injection. The trial had no body composition endpoint. It confirmed that CJC-1295 raises GH and IGF-1 durably. That is all it confirmed.
CJC-1295 development did not advance to Phase III. The body composition trial never ran. Every claim about CJC-1295 reducing fat or building muscle is transferred confidence from the GHRH class broadly, from tesamorelin's VAT data specifically, or from mechanistic reasoning about IGF-1 promoting lipolysis and protein synthesis in favorable conditions. That reasoning may be correct. But no completed RCT has tested it for body composition, and most competitor articles present the IGF-1 elevation data as if fat loss evidence were the logical consequence rather than an assumption.
The DAC version (CJC-1295 with DAC) extends half-life from roughly 30 minutes to about 8 days by covalently binding albumin. Sustained GH elevation versus pulsatile GH elevation has meaningfully different effects on receptor sensitivity over weeks: chronic GH exposure is associated with receptor downregulation that pulsatile dosing partially avoids. That trade-off also has no completed human RCT to resolve it. For a deeper look at the ipamorelin comparison and where CJC-1295 fits in the GHRH vs GHRP distinction, the ipamorelin vs CJC-1295 article covers the receptor-level difference in detail.
On regulatory access: both CJC-1295 and MK-677 were placed on FDA's Category 2 restricted compounding list in 2023. Following PCAC review in late 2024 and early 2025, both were reclassified in April 2026 and are now available through compounding pharmacies with a valid prescription.
The RCT Evidence Table: What Each Peptide Has Actually Proven
| Peptide | Strongest human evidence | Body comp endpoint? | Visceral fat reduced in RCTs? | Lean mass increased? | Primary side effect flag |
|---|---|---|---|---|---|
| Tesamorelin | 5 Phase III RCTs, 2026 meta-analysis (Obesity Research and Clinical Practice) | Yes (primary endpoint in all 5 trials) | Yes: 15-20% over 26 weeks | Modest improvement | Fluid retention, glucose elevation, arthralgia |
| MK-677 | 2-year RCT (Nass 2008, Annals of Internal Medicine), multiple 4-12 week studies | Yes (secondary endpoint in 2-year trial) | Not significant in 2-year trial | Yes: +1.1 kg vs -0.5 kg placebo over 24 months | Appetite increase, glucose elevation, edema, insulin resistance |
| CJC-1295 | 1 Phase 1/2 trial (Ionescu 2006, JCEM), 21 participants | No | No data | No data | No long-term human safety data |
Which One Should You Actually Use?
The answer depends on your goal and your metabolic baseline. These three compounds are not interchangeable. Their evidence bases point in different directions.
For Visceral Fat Reduction
Tesamorelin is the only evidence-backed choice for visceral fat specifically. Phase III trial data, a 2026 meta-analysis, and a clear mechanism support the 15-20% VAT reduction claim. The population caveat is real: every trial was in HIV-associated lipodystrophy. Off-label use in non-HIV metabolic patients is extrapolating from a different population. That extrapolation is mechanistically reasonable, but you should enter it with eyes open about what the actual trial populations looked like.
Access: brand-only (Egrifta or Egrifta WR), prescription required, HIV indication for on-label use. Not legally compoundable in the US.
For Lean Mass Over 12-24 Months
MK-677 has the strongest long-duration human data for lean mass in this comparison: 24 months of sustained IGF-1 elevation with DEXA-confirmed gains. The glucose trade-off is real. If your fasting glucose trends high, your fasting insulin is elevated, or you carry insulin-resistance genetic variants, MK-677's glucose-raising effect compounding on an existing risk deserves serious weight in your decision. Check fasting glucose and HbA1c before starting.
Access: compounding pharmacy with prescription as of April 2026, following PCAC reclassification.
For Protocol Flexibility (CJC-1295)
CJC-1295 dominates community protocols for dosing convenience (weekly with DAC), availability, and the plausible GHRH mechanism. The GH and IGF-1 elevation data from Ionescu 2006 are real. The body composition benefit is inferred, not directly demonstrated. If you use it and it works for you, that result is real. Know that the supporting evidence for the body composition claim comes from the broader GHRH class, not from CJC-1295's own trials.
Access: compounding pharmacy with prescription as of April 2026.
What Your GH Genetics Say About Which One Wins
The comparison is not the same for every genotype. Two variables change the outcome more than protocol design does.
GHR Exon 3 Deletion
Roughly 30-50% of the population carries at least one d3 allele at the growth hormone receptor locus. D3 carriers show stronger ERK signal amplification downstream of any GH pulse: more IGF-1 produced per unit of GH stimulus. For tesamorelin and MK-677, d3 carriers are more likely to replicate the outcomes seen in the trials. Fl/fl carriers (the lower-sensitivity configuration) may need longer protocol durations or higher dose frequencies to reach the same IGF-1 output. This is why two people on identical MK-677 25 mg daily protocols can have IGF-1 responses that differ by a factor of two: the receptor efficiency, not the dose, is the variable. The full GHR Exon 3 article covers the variant's effect size and what it means for dosing decisions.
Glucose and Insulin Risk
MK-677 elevated fasting glucose in the Nass two-year RCT and reduced insulin sensitivity in short-term pharmacodynamic studies by 15-34%. If you carry TCF7L2, PPARG, or other insulin-resistance-associated variants, or if your fasting glucose is already above 95 mg/dL, MK-677's glucose effect compounds an existing risk. Tesamorelin also carries a glucose signal (IGF-1-driven), but it was smaller in the trial data than MK-677's ghrelin-mediated effect. Your choice between the two should weight this heavily.
For a full picture of how off-cycle GH receptor dynamics affect how long you should run a secretagogue protocol before taking a break, see how long GH receptors take to reset. And to see where tesamorelin ranks in your specific genetic profile, the tesamorelin peptide page outlines the SNPs our report analyzes and how they affect the VAT reduction outcome.
Verdict: Tesamorelin is the only GH peptide in this comparison with Phase III RCT evidence for visceral fat reduction. MK-677 has the longest human lean-mass data but did not reduce fat in trials and raises glucose. CJC-1295 has no completed body composition trial.
For visceral fat, tesamorelin is the evidence-backed call with the HIV population caveat. For lean mass over 12-24 months, MK-677's data is the strongest here. For CJC-1295: run it knowing the body composition support is inferred from the GHRH class, not from its own completed trials. Your GHR genotype changes how much IGF-1 any of these compounds actually generate for you, which changes which one is worth the trade-offs. Upload your DNA or order a kit to see how your GH axis genetics rank all three compounds for your specific profile.
Your DNA shapes how you respond to each of these.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Does tesamorelin work for fat loss if I don't have HIV?
All five Phase III RCTs for tesamorelin were conducted in HIV-positive patients with antiretroviral-induced lipodystrophy. There is no completed RCT of tesamorelin for body composition in metabolically healthy, non-HIV adults. The GHRH mechanism that drives its visceral fat reduction is not HIV-specific, so off-label extrapolation is mechanistically reasonable. But you should know you are extrapolating from a different population, not directly applying a result that was tested in people like you.
How does MK-677 compare to tesamorelin for losing belly fat?
Tesamorelin outperforms MK-677 on the available evidence for visceral fat specifically. The 2026 Obesity Research and Clinical Practice meta-analysis showed 15-20% visceral fat reduction with tesamorelin over 26 weeks. MK-677's two-year Nass trial did not show significant fat mass reduction, though it produced sustained lean mass gains. MK-677 also raises appetite via ghrelin mimicry, which can work against fat loss goals. If visceral fat reduction is the primary objective, tesamorelin has stronger direct evidence.
Is CJC-1295 safe for long-term use?
No long-term human safety data exists for CJC-1295. The only human trial (Ionescu 2006) ran for a short duration in 21 participants and reported no serious adverse events at doses up to 60 mcg/kg. Multiple doses maintained elevated IGF-1 for 28 days or more without serious events in that small cohort. What happens with continuous use over 12-24 months has not been studied. Sustained GH elevation carries potential risks including fluid retention, glucose elevation, and theoretical IGF-1-driven tissue effects that are separate from the short-term tolerability profile.
How long does it take for MK-677 to show body composition changes?
The Nass two-year RCT showed measurable lean mass gains that accumulated continuously over 24 months, with IGF-1 elevation sustained throughout. Short-term studies (4-12 weeks) show IGF-1 elevation within the first week but body composition changes typically require 8-12 weeks to register on DEXA. Fat mass was not significantly reduced in the two-year trial, so if fat loss is your metric, MK-677 may not deliver it regardless of duration. Lean mass gains were real but did not translate to functional performance improvements on any test in the trial.
Can you stack MK-677 with CJC-1295?
Some practitioners combine them because MK-677 activates GHS-R1a (the ghrelin receptor) while CJC-1295 activates GHRHR (the GHRH receptor), meaning they operate on different parts of the GH axis and are mechanistically synergistic. There are no controlled trials of the combination with body composition endpoints. The main practical concern with stacking them is additive glucose elevation: both compounds raise fasting glucose and reduce insulin sensitivity through different mechanisms, and the combined glucose effect may exceed what either produces alone.
What is the difference between tesamorelin and CJC-1295?
Both are GHRH analogs that trigger GH release by binding the GHRH receptor. Tesamorelin is a modified form of natural GHRH with a stabilizing trans-3-hexenoic acid group that extends its half-life from about 3 minutes to roughly 30 minutes. CJC-1295 with DAC binds albumin to extend duration to about 8 days per injection. The critical difference is evidence: tesamorelin has five completed Phase III RCTs with visceral fat as the primary endpoint. CJC-1295 has one Phase 1/2 pharmacokinetic trial with no body composition endpoint. Tesamorelin is also FDA-approved and not legally compoundable; CJC-1295 returned to compoundable status in April 2026.
Why does MK-677 raise blood sugar?
MK-677 mimics ghrelin, and ghrelin is naturally associated with glucose elevation and reduced insulin sensitivity. Additionally, the IGF-1 elevation that MK-677 produces can paradoxically increase hepatic glucose output in some individuals. In the Nass two-year trial, fasting glucose was elevated in the MK-677 group relative to placebo. Short-term pharmacodynamic studies put the insulin sensitivity reduction at 15-34% at therapeutic doses. If you have pre-existing insulin resistance, family history of type 2 diabetes, or carry relevant genetic variants like TCF7L2, this side effect deserves significant weight in your decision about whether to use MK-677.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.